Study of HN2302 for hard-to-treat myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have generalized myasthenia gravis (not just eye symptoms) and have antibodies called AchR or MuSK
- Your MG symptoms are moderate to severe, with an ADL score of 6 or higher
- Your current treatments haven't worked well enough or have become ineffective
- You don't have serious infections, a history of organ transplantation, or severe heart or brain conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy using special immune cells (CAR-NK cells) that may help people whose myasthenia gravis has not improved with standard treatments. It aims to see if these cells can reduce muscle weakness and improve daily life.
This study tests a new medicine called HN2301 for people with generalized myasthenia gravis that has not improved with standard treatments. The goal is to see if it is safe and if it helps reduce symptoms.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
Hear when a new Refractory Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.